America August 10, 2026
$1.32 Billion for a Molecule: Jazz Pharmaceuticals Bets on Rare-Epilepsy Drug With No Approved Rivals
There are roughly 2,500 people in the United States living with KCNT1+ epilepsy. There is currently not a single FDA-approved…
